Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3047-3053

  Fenner, Lukas ^a   Egger, Matthias ^a   Bodmer, Thomas ^a   Altpeter, Ekkehardt ^b   Zwahlen, Marcel ^a   Jaton, Katia ^c   Pfyffer, Gaby E ^d   Borrell, Sonia ^e,f   Dubuis, Olivier ^g   Bruderer, Thomas ^h   Siegrist, Hans H ⁱ   Furrer, Hansjakob ^j   Calmy, Alexandra ^k   Fehr, Jan ^l   Stalder, Jesica Mazza ^c   Ninet, Béatrice ^k   Böttger, Erik C ^m   Gagneux, Sebastien ^e,f  

^a UNIVERSITY OF BERN   (Switzerland)

^b FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Luzerner Kantonsspital ^*  (Switzerland)

^e SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

^g Viollier AG   (Switzerland)

^h Centre for Laboratory Medicine   (Switzerland)

ⁱ ADMed Microbiology   (Switzerland)

^j UNIVERSITY OF BERN   (Switzerland)

^k GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m UNIVERSITY OF ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; ETHAMBUTOL; INHA PROTEIN; ISONIAZID; KATG PROTEIN; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENETICS; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; FEMALE; GENE CLUSTER; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SWITZERLAND;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; GENOTYPE; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84861172979     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06460-11     Document Type: Article

References (39)

1. Baker L, Brown T, Maiden MC, Drobniewski F. 2004. Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg. Infect. Dis. 10:1568 -1577.
2. Blumberg HM, et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603- 662.
3. Borrell S, Gagneux S. 2009. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13:1456 -1466.
4. Borrell S, Gagneux S. 2011. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin. Microbiol. Infect. 17:815-820.
5. Böttger EC. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin. Microbiol. Infect. 17:1128 -1134.
6. Böttger EC, Pletschette M, Andersson D. 2005. Drug resistance and fitness in Mycobacterium tuberculosis infection. J. Infect. Dis. 191:823-824. (Pubitemid 40271079)
7. Böttger EC, Springer B. 2008. Tuberculosis: drug resistance, fitness, and strategies for global control. Eur. J. Pediatr. 167:141-148.
8. Böttger EC, Springer B, Pletschette M, Sander P. 1998. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat. Med. 4:1343-1344. (Pubitemid 28553445)
9. Brosch R, et al. 2002. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc. Natl. Acad. Sci. U. S. A. 99:3684-3689. (Pubitemid 34252166)
10. Comas I, et al. 2012. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 44:106-110.
11. Dos Vultos T, et al. 2008. Evolution and diversity of clonal bacteria: the paradigm of Mycobacterium tuberculosis. PLoS One 3:e1538.
12. Fenner L, et al. 2012. Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. J. Clin. Microbiol. 50:388-395.
13. Fenner L, et al. 2011. "Pseudo-Beijing": evidence for convergent evolution in the direct repeat region of Mycobacterium tuberculosis. PLoS One 6:e24737.
14. Gagneux S, et al. 2006. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog. 2:e61.
15. Gagneux S, et al. 2006. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 103:2869-2873.
16. Gagneux S, et al. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944-1946. (Pubitemid 43993719)
17. Gagneux S, Small PM. 2007. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect. Dis. 7:328-337. (Pubitemid 46590063)
18. Hazbon MH, et al. 2006. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50:2640-2649. (Pubitemid 44198682)
19. Johnson R, et al. 2006. Ethambutol resistance testing by mutation detection. Int. J. Tuberc. Lung Dis. 10:68-73. (Pubitemid 43266280)
20. Johnston JC, Shahidi NC, Sadatsafavi M, FitzGerald JM. 2009. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 4:e6914.
21. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. 2008. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 12:129-145.
22. Kim SJ. 2005. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur. Respir. J. 25:564-569. (Pubitemid 40331189)
23. Lipin MY, Stepanshina VN, Shemyakin IG, Shinnick TM. 2007. Association of specific mutations in katG, rpoB, rpsL and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia. Clin. Microbiol. Infect. 13:620-626. (Pubitemid 46730669)
24. Mitchison DA, et al. 1960. A comparison of the virulence in guinea-pigs of South Indian and British tubercle bacilli. Tubercle 41:1-22.
25. Parwati I, van Crevel R, Van Soolingen D. 2010. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis genotype strains. Lancet Infect. Dis. 10:103-111.
26. Portevin D, Gagneux S, Comas I, Young D. 2011. Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog. 7:e1001307.
27. Pym AS, Saint-Joanis B, Cole ST. 2002. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect. Immun. 70:4955-4960.
28. Sander P, et al. 2002. Fitness cost of chromosomal drug resistanceconferring mutations. Antimicrob. Agents Chemother. 46:1204-1211. (Pubitemid 34415292)
29. Sandgren A, et al. 2009. Tuberculosis drug resistance mutation database. PLoS Med. 6:e2.
30. Shanmugam S, Selvakumar N, Narayanan S. 2011. Drug resistance among different genotypes of Mycobacterium tuberculosis isolated from patients from Tiruvallur, South India. Infect. Genet. Evol. 11:980-986.
31. Sherman DR, et al. 1996. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272:1641-1643. (Pubitemid 26200020)
32. Springer B, Calligaris-Maibach RC, Ritter C, Böttger EC. 2008. Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping. J. Clin. Microbiol. 46:4064-4067.
33. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Böttger EC. 2009. Quantitative susceptibility testing of Mycobacterium tuberculosis by use of MGIT960 and EpiCenter instrumentation. J. Clin. Microbiol. 47:1773-1780.
34. Sreevatsan S, et al. 1997. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc. Natl. Acad. Sci. U. S. A. 94:9869-9874. (Pubitemid 27408157)
35. Supply P, et al. 2006. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J. Clin. Microbiol. 44:4498-4510. (Pubitemid 44937085)
36. Telenti A, et al. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650. (Pubitemid 23083244)
37. Tsolaki AG, et al. 2005. Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of Mycobacterium tuberculosis. J. Clin. Microbiol. 43:3185-3191. (Pubitemid 40981321)
38. van Soolingen D, et al. 2000. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in The Netherlands. J. Infect. Dis. 182:1788-1790.
39. Wright A, et al. 2009. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373:1861-1873.